Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemiaARLINGHAUS, Ralph B.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8560-8567, issn 0950-9232, 8 p., NS7Article

Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemiaARLINGHAUS, Ralph B.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8560-8567, issn 0950-9232, 8 p.Article

CML: Molecular Mechanisms & Therapeutic StrategiesARLINGHAUS, Ralph B.Oncogene (Basingstoke). 2002, Vol 21, Num 56, issn 0950-9232, 141 p., NS7Serial Issue

CML: Molecular mechanisms & therapeutic strategiesARLINGHAUS, Ralph B.Oncogene (Basingstoke). 2002, Vol 21, Num 56, issn 0950-9232, 141 p.Serial Issue

BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instabilitySKORSKI, Tomasz.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8591-8604, issn 0950-9232, 14 p.Article

The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine modelRUIBAO REN.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8629-8642, issn 0950-9232, 14 p.Article

Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent miceXIAOYANG LING; ARLINGHAUS, Ralph B.Cancer research (Baltimore). 2005, Vol 65, Num 7, pp 2532-2536, issn 0008-5472, 5 p.Article

BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instabilitySKORSKI, Tomasz.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8591-8604, issn 0950-9232, 14 p., NS7Article

The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine modelREN, Ruibao.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8629-8642, issn 0950-9232, 14 p., NS7Article

Philadelphia-positive leukemia: a personal perspectiveHEISTERKAMP, Nora; GROFFEN, John.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8536-8540, issn 0950-9232, 5 p.Article

Philadelphia-positive leukemia: a personal perspectiveHEISTERKAMP, Nora; GROFFEN, John.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8536-8540, issn 0950-9232, 5 p., NS7Article

BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemiaSALESSE, Stephanie; VERFAILLIE, Catherine M.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8547-8559, issn 0950-9232, 13 p., NS7Article

Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteinsPERROTTI, Danilo; CALABRETTA, Bruno.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8577-8583, issn 0950-9232, 7 p., NS7Article

BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemiaSALESSE, Stephanie; VERFAILLIE, Catherine M.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8547-8559, issn 0950-9232, 13 p.Article

Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteinsPERROTTI, Danilo; CALABRETTA, Bruno.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8577-8583, issn 0950-9232, 7 p.Article

Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CMLSALESSE, Stephanie; VERFAILLIE, Catherine M.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8605-8611, issn 0950-9232, 7 p., NS7Article

Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CMLSALESSE, Stephanie; VERFAILLIE, Catherine M.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8605-8611, issn 0950-9232, 7 p.Article

Inhibition of the Bcr-abl tyrosine kinase as a therapeutic strategy for CMLDRUKER, Brian J.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8541-8546, issn 0950-9232, 6 p., NS7Article

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571NIMMANAPALLI, Ramadevi; BHALLA, Kapil.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8584-8590, issn 0950-9232, 7 p.Article

Studying the pathogenesis of BCR-ABL⁺ leukemia in miceVAN ETTEN, Richard A.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8643-8651, issn 0950-9232, 9 p.Article

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571NIMMANAPALLI, Ramadevi; BHALLA, Kapil.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8584-8590, issn 0950-9232, 7 p., NS7Article

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CMLDRUKER, Brian J.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8541-8546, issn 0950-9232, 6 p.Article

Studying the pathogenesis of BCR-ABL⁺ leukemia in miceVAN ETTEN, Richard A.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8643-8651, issn 0950-9232, 9 p., NS7Article

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesKANTARJIAN, Hagop M; CORTES, Jorge E; BOCHINSKI, Kathy et al.Blood. 2003, Vol 101, Num 1, pp 97-100, issn 0006-4971, 4 p.Article

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1―BCR-ABL―JAK2 ComplexMIN CHEN; GALLIPOLI, Paolo; LAMBIE, Karen et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 6, pp 405-423, issn 0027-8874, 19 p.Article